Immuneering (IMRX) investor relations material

12-month overall survival and efficacy results

• 12-month overall survival reached 64% for first-line pancreatic cancer patients treated with atebumetanib plus chemotherapy, nearly double the 35% benchmark from standard of care, with median overall survival not yet reached at a median follow-up of 13.4 months.

• Median progression-free survival was 8.5 months versus 5.5 months for standard of care; overall response rate was 39% (vs. 23%), and disease control rate was 81% (vs. 48%).

• Consistent survival benefit observed over time: 27-point separation at 6 months, 36-point at 9 months, and 29-point at 12 months compared to standard of care.

• Expanded cohort of over 50 patients is showing survival trends consistent with the original 34-patient cohort, with updated data to be reported in the first half of 2026.

• The study population was older (median age 69), with over two-thirds above 65, reinforcing the significance of the results.

Safety, tolerability, and quality of life

• Atebumetanib plus chemotherapy demonstrated a favorable safety profile, with only anemia and neutropenia as Grade 3 adverse events in over 10% of patients; no new safety signals identified.

• Grade 3 neutropenia and anemia each occurred in 18% of patients, lower or comparable to rates in pivotal studies of other regimens.

• No Grade 5 events were reported in the study cohort.

• Patients experienced meaningful improvements in quality of life, including weight gain, improved appetite, and increased independence, as highlighted in a case study.

• Quality of life metrics will be included as secondary endpoints in the upcoming Phase 3 trial.

Next steps and future plans

• A pivotal global Phase 3 trial (MapKeeper 301) will enroll approximately 510 patients, comparing atebumetanib plus chemotherapy to standard of care, with overall survival as the primary endpoint; first patient dosing expected mid-year and top-line results anticipated in mid-2028.

• Additional data from the expanded cohort and circulating tumor DNA analyses will be reported in the first half of the year.

• Phase 2 combination studies in non-small cell lung cancer are planned to start in 2026, including combinations with Libtayo.

• The company is well-funded with a cash runway into 2029, supporting ongoing and future studies.